Article info

Original research
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Authors

  1. Correspondence to Associate Professor Yoland Antill; Yoland.Antill{at}monash.edu
View Full Text

Citation

Antill Y, Kok P, Robledo K on behalf of the Australia New Zealand Gynaecological Oncology Group (ANZGOG), et al
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Publication history

  • Accepted March 31, 2021
  • First published June 8, 2021.
Online issue publication 
February 24, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.